|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.128 SEK | -0.88% |
|
-9.76% | +22.08% |
| 05-22 | Intervacc AB Completes Successful Evaluation of Us Strain of Strangles Pathogen Ahead of Clinical Trials | CI |
| 05-15 | Sweden's Intervacc Elects New Chair | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 40.01M | - | ||||
| 55.57B | |||||
| 54.26B | |||||
| 23.35B | - | ||||
| 23.54B | - | ||||
| 20.32B |
- Stock Market
- Stocks
- IVACC Stock
- Charts Intervacc AB
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
